AG2R LA Mondiale Gestion D Actifs Makes New $7.04 Million Investment in Thermo Fisher Scientific Inc. $TMO

Key Points

• AG2R LA Mondiale Gestion D Actifs acquired 14,155 shares of Thermo Fisher Scientific Inc. in a deal valued at approximately $7,044,000, indicating strong institutional interest.
• Thermo Fisher Scientific reported earnings per share (EPS) of $5.36 for the last quarter, exceeding analyst expectations of $5.22, and also showed a year-over-year revenue increase of 2.9% to $10.86 billion.
• The company announced a quarterly dividend of $0.43 per share, set to be paid on October 15th, with a current dividend yield of 0.4% and a payout ratio of 9.95%.

AG2R LA Mondiale Gestion D Actifs purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 14,155 shares of the medical research company's stock, valued at approximately $7,044,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of TMO. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $25,000. CBIZ Investment Advisory Services LLC lifted its holdings in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after acquiring an additional 33 shares during the last quarter. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $30,000. Anderson Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth about $30,000. Finally, Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth about $31,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Down 2.4%

Shares of TMO traded down $11.93 during midday trading on Friday, reaching $479.48. 1,543,232 shares of the stock were exchanged, compared to its average volume of 1,509,627. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $623.77. The firm has a 50 day simple moving average of $466.86 and a 200-day simple moving average of $450.58. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market cap of $181.06 billion, a price-to-earnings ratio of 27.73, a P/E/G ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the business earned $5.37 EPS. The business's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the transaction, the chief executive officer directly owned 113,762 shares of the company's stock, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 in the last three months. Corporate insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. William Blair initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Finally, Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. Seventeen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $592.24.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.